Physician profile
Jeffrey M Mcdaniel
NPI 1366576282
$4,205.73
in general payments reported to CMS, 2019-2025
35 companies · $596 in 2025
The $596 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $914 · 2021: $775 · 2022: $158 · 2023: $374 · 2024: $577 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $488.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $464.57 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.31 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $304.17 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $275.35 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.36 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $164.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $138.84 | 2019-2021 | |
| Pfizer INC. | $129.67 | 2019-2025 | |
| Allergan, INC. | $113.20 | 2019-2020 | |
| Antares Pharma, INC. | $104.93 | 2019-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $74.67 | 2019-2021 | |
| Abbvie INC. | $72.77 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $70.95 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69.06 | 2019-2020 | |
| Adlon Therapeutics L.P. | $65.15 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.22 | 2019-2021 | |
| Pacira Therapeutics, INC. | $54.12 | 2020 | |
| Abbott Laboratories | $45.17 | 2024-2025 | Freestyle Libre |
| Genentech USA, INC. | $39.55 | 2021 | |
| Astellas Pharma US INC | $34.85 | 2020-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $31.71 | 2019-2020 | |
| Eisai INC. | $26.03 | 2020-2021 | |
| Rhythm Pharmaceuticals, INC. | $23.03 | 2024 | Imcivree |
| Hologic Sales and Service, LLC | $20.59 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.02 | 2024 | Voquezna |
| Organon LLC | $18.34 | 2021 | |
| Hologic INC | $17.60 | 2021 | |
| Radius Health, INC. | $16.22 | 2019 | |
| Shire North American Group INC | $15.18 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.13 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.86 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.73 | 2021 | |
| Phadia US INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.